Last reviewed · How we verify
Long DAPT
Long DAPT extends dual antiplatelet therapy duration to reduce thrombotic cardiovascular events in patients with acute coronary syndrome or those undergoing percutaneous coronary intervention.
Long DAPT extends dual antiplatelet therapy duration to reduce thrombotic cardiovascular events in patients with acute coronary syndrome or those undergoing percutaneous coronary intervention. Used for Acute coronary syndrome post-percutaneous coronary intervention with stent placement, Prevention of stent thrombosis and recurrent ischemic events in high-risk patients.
At a glance
| Generic name | Long DAPT |
|---|---|
| Also known as | 12 months ASA + Clopidogrel |
| Sponsor | Federico II University |
| Drug class | Antiplatelet therapy regimen |
| Target | P2Y12 receptor and cyclooxygenase (COX) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
DAPT (Dual Antiplatelet Therapy) combines two antiplatelet agents, typically aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor), to prevent stent thrombosis and recurrent ischemic events. Long DAPT refers to extended treatment duration beyond standard 12 months, aiming to further reduce atherothrombotic complications in high-risk patients, though at the cost of increased bleeding risk.
Approved indications
- Acute coronary syndrome post-percutaneous coronary intervention with stent placement
- Prevention of stent thrombosis and recurrent ischemic events in high-risk patients
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Intracranial hemorrhage
Key clinical trials
- The 10-Year Extended Follow-up of the DACAB Trial
- HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN) (PHASE3)
- The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients (PHASE4)
- Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND (PHASE4)
- Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure in Dialyzed Patients (PHASE4)
- Drug-Coated Balloon in Anticoagulated and Bleeding Risk Patients Undergoing PCI (NA)
- STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial (NA)
- Intensive Drug Therapy for Ischemic Stroke Caused by Severe Intracranial Arterial Stenosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Long DAPT CI brief — competitive landscape report
- Long DAPT updates RSS · CI watch RSS
- Federico II University portfolio CI